Aspirin for Colorectal Cancer Chemoprevention: A Bleeding Risk Weighed Against a Cancer Risk
A single average-risk patient asking about daily aspirin for colorectal cancer prevention, testing whether a real reduction in cancer risk still justifies a real increase in bleeding risk once population-level guidance is applied to one specific person.
Preston A., a 47-year-old man who works as an insurance claims adjuster, brought up daily aspirin himself at what was otherwise a routine preventive visit, prompted by his father's colorectal cancer diagnosis at 61 and a coworker's recent recommendation that he "just start taking a baby aspirin" the way people used to tell everyone to. His own colonoscopy risk assessment doesn't meet formal high-risk criteria — one affected first-degree relative diagnosed after age 60 places him at only modestly elevated risk, not enough to change his own screening interval — but the family history weighs on him more than the numbers alone convey, and he's specifically asking whether aspirin is something he should simply start now, at 47, rather than wait on.
The honest answer requires walking him through a genuine reversal in how this question has been answered over time, not just handing him a yes or no. For years, aspirin's case for colorectal cancer chemoprevention rested on real evidence — decades of cohort follow-up and pooled analyses of cardiovascular-prevention trials showing reduced colorectal cancer incidence and mortality with sustained use. What changed in 2022 is subtler than a reversal, and the distinction is the whole answer: the USPSTF did not recommend against aspirin for colorectal cancer, it dropped colorectal cancer from the recommendation entirely, retitling the statement to cardiovascular disease alone and concluding the evidence is INADEQUATE to determine whether aspirin reduces CRC incidence or mortality. Its evidence review is why. Within the randomized periods themselves, the Women's Health Study — 100mg on alternate days, not daily — found no significant CRC effect at ten years, and ASPREE, in adults 70 and older, found higher colorectal cancer mortality at five years. The benefit that survives is concentrated in observational follow-up beyond the trials, which is exactly the evidence a task force cannot build a recommendation on.
The two bodies of evidence aren't contradictory once their populations are named: one describes people who began aspirin relatively young and were followed observationally for decades, the other describes randomized initiation at 70 and above. Preston at 47 is in neither. The pooled cohort analysis that speaks most directly to him found reduced colorectal cancer risk in people who started before 70 and kept going, and no reduction in those who started after — a finding about timing that no current recommendation is built on, and that he is being asked to act on twenty-three years before the trials would have enrolled him.
Primary care, a patient-initiated aspirin question
I'd be inclined to support starting low-dose aspirin. There's decades of accumulated cohort evidence showing real reductions in colorectal cancer incidence and mortality with sustained use over many years, and a pooled analysis of two large cohorts found the reduction specifically in people who started before 70 and continued. Given his family history, even if it doesn't formally elevate his screening risk category, I don't think it's unreasonable for him to want that additional protection starting now, relatively young, with decades of use ahead of him.
I'd recommend against starting it, and I want to be careful about what the guidance actually says, because it's weaker than "don't" and that matters. The USPSTF didn't rule against aspirin for colorectal cancer in 2022 — it removed colorectal cancer from the recommendation and said the evidence is inadequate to judge. Its review found the Women's Health Study null for CRC at ten years and ASPREE showing higher CRC mortality at five. So I'm not citing a prohibition, I'm citing a body that looked at this carefully and declined to say anything at all, which for a healthy 47-year-old asking me to start a lifelong drug is close enough to an answer.
I don't think either of you is wrong about the data — I think you're each weighting a different population's evidence, and the honest answer is that the population matters here. The original long-term benefit signal comes largely from cohorts starting aspirin relatively young and followed for decades. ASPREE enrolled adults 70 and older — 65 and older for US minority participants — with a mean age of 74, where bleeding risk climbs with age in ways it doesn't for a 47-year-old with no bleeding risk factors of his own. Preston isn't the ASPREE population, and he isn't formally high-risk enough to trigger a chemoprevention indication on cancer-risk grounds alone either. I'd tell him honestly that current guideline-level evidence doesn't support starting aspirin specifically for cancer prevention at his risk level, while being clear that his own individual numbers — young, no bleeding risk factors — sit in the part of the evidence base least like the population the reversal was actually built on. That's not a recommendation to start; it's context for a decision that's genuinely his to make once he understands both sides honestly.
Not started: aspirin chemoprevention was explicitly not recommended today, consistent with current USPSTF guidance, with the full reasoning — the guideline reversal, ASPREE's findings, and how his own age and bleeding-risk profile compare to both the older and newer evidence bases — walked through directly rather than delivered as a flat no. Preston left the visit understanding the decision rather than simply accepting it, with the door explicitly left open to revisit if his personal risk profile changes.